Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010 / LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO.

Biotechnology

Outlook Therapeutics

C. Russell Trenary III

Tony Moses

Surendra Sharma

Christoph Puetz

Lauren Nelson

Kathleen Billman

Jennifer Kissner

Entisar Dahan, MPM, PHR

Anu Wallecha

Terry Dagnon

Lawrence A. Kenyon

Jeff Evanson

Directors

Operations Team

Leadership Team

Vice Presidents

Teams at Outlook Therapeutics

Directors

Operations Team

Leadership Team

Vice Presidents